Catalyst Capital Advisors LLC Raises Position in DexCom, Inc. (NASDAQ:DXCM)

Catalyst Capital Advisors LLC grew its holdings in DexCom, Inc. (NASDAQ:DXCM) by 236.5% during the fourth quarter, HoldingsChannel reports. The firm owned 1,033 shares of the medical device company’s stock after acquiring an additional 726 shares during the period. Catalyst Capital Advisors LLC’s holdings in DexCom were worth $80,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. Versant Capital Management Inc purchased a new position in DexCom in the 4th quarter worth approximately $25,000. Heck Capital Advisors LLC purchased a new position in DexCom in the 4th quarter worth approximately $38,000. MassMutual Private Wealth & Trust FSB lifted its stake in DexCom by 46.7% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company’s stock worth $65,000 after purchasing an additional 265 shares in the last quarter. RPg Family Wealth Advisory LLC purchased a new position in DexCom in the 3rd quarter worth approximately $57,000. Finally, Park Place Capital Corp lifted its stake in DexCom by 3,516.7% in the 4th quarter. Park Place Capital Corp now owns 868 shares of the medical device company’s stock worth $68,000 after purchasing an additional 844 shares in the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on DXCM shares. Wells Fargo & Company raised their target price on shares of DexCom from $90.00 to $94.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 11th. JPMorgan Chase & Co. lifted their price target on shares of DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a research report on Friday, October 25th. StockNews.com lowered shares of DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. Sanford C. Bernstein lifted their price target on shares of DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a research report on Friday, October 25th. Finally, Raymond James reduced their price target on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a research report on Friday, October 25th. Four analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $99.06.

Insiders Place Their Bets

In other news, EVP Jereme M. Sylvain sold 2,090 shares of DexCom stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $181,641.90. Following the completion of the sale, the executive vice president now directly owns 83,526 shares of the company’s stock, valued at approximately $7,259,244.66. The trade was a 2.44 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Jacob Steven Leach sold 2,634 shares of DexCom stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $228,920.94. Following the sale, the chief operating officer now directly owns 268,644 shares of the company’s stock, valued at approximately $23,347,850.04. This trade represents a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 38,083 shares of company stock worth $3,309,794 over the last 90 days. Corporate insiders own 0.30% of the company’s stock.

DexCom Stock Performance

NASDAQ:DXCM opened at $90.53 on Wednesday. The company has a fifty day simple moving average of $82.65 and a two-hundred day simple moving average of $75.62. The company has a market cap of $35.36 billion, a price-to-earnings ratio of 54.21, a price-to-earnings-growth ratio of 2.26 and a beta of 1.14. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 31.40% and a net margin of 17.22%. As a group, equities analysts anticipate that DexCom, Inc. will post 1.69 earnings per share for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.